Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (281-290 of 910) with videos related to

Pageof 91
Sort By:
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
American Heart Journal|March 30, 2006
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarctionPaul W Armstrong, Kenneth W Mahaffey, Wei-Ching Chang, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
Coronary Artery Disease|January 6, 2012
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarctionJames S Mills, Kenneth W Mahaffey, Yuliya Lokhnygina, et al.
European Heart Journal. Acute Cardiovascular Care|May 17, 2022
Targeted temperature management after out of hospital cardiac arrest: quo vadis?Konstantin A Krychtiuk, Christopher B Fordyce, Carolina M Hansen, et al.
Pageof 91

Showing results (281-290 of 910) with videos related to

Sort By:
Pageof 91
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
American Heart Journal|March 30, 2006
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarctionPaul W Armstrong, Kenneth W Mahaffey, Wei-Ching Chang, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
Coronary Artery Disease|January 6, 2012
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarctionJames S Mills, Kenneth W Mahaffey, Yuliya Lokhnygina, et al.
European Heart Journal. Acute Cardiovascular Care|May 17, 2022
Targeted temperature management after out of hospital cardiac arrest: quo vadis?Konstantin A Krychtiuk, Christopher B Fordyce, Carolina M Hansen, et al.
Pageof 91